GlaxoSmithKline Czech Republic made a net profit of CZK 125 mil under revenues of CZK 4,378 mil in 2015, up 42.1% and -9.83%, respectively, when compared to the last year. This translates into a net margin of 2.85%.
Historically, the firm’s net profit reached an all time high of CZK 240 mil in 2011 and an all time low of CZK -7.67 mil in 2006. Since 2010, the firm's net profit has increased -24.6% or -5.49% a year on average.
On the operating level, EBITDA reached CZK 139 mil, up -0.486% when compared to the previous year. Over the last five years, company's EBITDA has grown -10.6% a year on average.
As far as GlaxoSmithKline Czech Republic's peers are concerned, Roche Czech Republic posted net and EBITDA margin of 0.936% and 3.84%, respectively in 2015, Bayer Czech Republic generated margins of 2.89% and 3.93% and Amgen Czech Republic's profit margin reached 5.93% on the net and 7.66% on the EBITDA level in 2015.